---
title: "CervoMed climbs 4% during regular trading on patent approval, $10M offering"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290234754.md"
description: "CervoMed rose 3.7% to $3.951 after US patent approval for neflamapimod through 2042 and $10M registered direct offering."
datetime: "2026-06-18T18:20:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290234754.md)
  - [en](https://longbridge.com/en/news/290234754.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290234754.md)
---

# CervoMed climbs 4% during regular trading on patent approval, $10M offering

CervoMed(CRVO.US) 盘中涨**3.7%**，现报**3.951**美元。

消息面上，公司近期获美国专利局批准 neflamapimod 用于治疗纯路易体痴呆症，专利保护期延至 2042 年。此外，CervoMed 宣布 1000 万美元注册直接发行，资金用于营运资本和一般公司用途。

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)

## Related News & Research

- [Cervo posts investor presentation on website covering clinical, development and financial updates](https://longbridge.com/en/news/289829022.md)
- [CervoMed Posts Updated Investor Presentation and Business Overview](https://longbridge.com/en/news/289834335.md)
- [CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | CRVO Stock News](https://longbridge.com/en/news/290228255.md)
- [Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)](https://longbridge.com/en/news/289519604.md)
- [CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | CRVO Stock News](https://longbridge.com/en/news/289591456.md)